Table 1.
Composition of CHS solid dispersions and corresponding physical mixtures.
Fig 1.
Comparative in vitro dissolution profiles of pure CHS, SDs and commercial tablet.
a) SDs with poloxamer 407 b) SDs with macrogol 6000 c) SDs with povidone d) SDs with copovidone.
Table 2.
The amount of dissolved CHS after 60 min from SDs and PMs.
Table 3.
Clopidogrel content in selected SDs (initially, and after 12 months of stability studies).
Fig 2.
DSC curves of CHS, poloxamer 407, and SDs with poloxamer 407 (P5 and P9) initially, and after 12 months of stability studies.
Fig 3.
DSC curves of CHS, macrogol 6000, and SDs with macrogol 6000 (M5 and M9) initially, and after 12 months of stability studies.
Fig 4.
DSC curves of CHS, copovidone, and SDs with copovidone (C5 and C9) initially, and after 12 months of stability studies.
Fig 5.
FT-IR spectra of CHS, poloxamer 407, and SDs with poloxamer 407 (P5 and P9) initially, and after 12 months of stability studies.
Fig 6.
FT-IR spectra of CHS, macrogol 6000, and SDs with macrogol 6000 (M5 and M9) initially, and after 12 months of stability studies.
Fig 7.
FT-IR spectra of CHS, copovidone, and SDs with copovidone (C5 and C9) initially, and after 12 months of stability studies.
Fig 8.
Comparative dissolution profiles of selected SDs after 12 months of stability studies.
Table 4.
Release kinetic of dissolution data (initially and after 12 months of stability studies).